文献速递毛发、甲与色素性疾病

BRAVE-AA2:巴瑞替尼4mg治疗重度斑秃减量至2mg的152周结局

Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2.
PubMed 文献 · J Am Acad Dermatol · 2024-10-22

BRAVE-AA2 Ⅲ期试验减量亚研究纳入546例重度斑秃成人(SALT≥50),52周时达到临床应答(SALT≤20)的巴瑞替尼4mg患者按1:1随机维持4mg或减至2mg。152周时,4mg组88.6%(39/44)维持应答,减量组58.5%(24/41)维持应答;减量前持续应答且SALT≤5者疗效丢失较少。

要点

  • 巴瑞替尼4mg治疗52周达SALT≤20者中36.8%(86/234)符合减量条件。
  • 减量至2mg后超过半数患者(58.5%)在152周仍维持临床应答。
  • 减量前持续应答且SALT≤5者减量后疗效丢失风险更低。

核心结论

  • 减量至2mg后超过半数患者维持应答。
  • 持续治疗应答和/或近乎完全毛发再生可能与减量后更易维持应答相关。

研究设计与样本

  • BRAVE-AA2为Ⅲ期试验,纳入546例重度斑秃成人(SALT评分≥50)。
  • 巴瑞替尼4mg治疗52周达临床应答(SALT≤20)者按1:1随机维持4mg或减量至2mg。
  • 缺失或删失数据采用末次观测结转法填补。

主要发现

  • 52周时86/234(36.8%)巴瑞替尼4mg治疗者符合减量条件,44例维持4mg,42例减量至2mg。
  • 152周时4mg组39/44(88.6%)维持临床应答,减量组24/41(58.5%)维持应答。
  • 减量患者中,52周时持续应答且SALT≤5者疗效丢失较少见。

关键数值与推荐

  • 重度斑秃定义为SALT评分≥50。
  • 临床应答定义为SALT评分≤20。
  • 减量条件为巴瑞替尼4mg治疗52周时达到临床应答。

临床怎么用

  • 对巴瑞替尼4mg治疗52周达SALT≤20的重度斑秃患者,可考虑减量至2mg并密切监测。
  • 减量前持续应答且SALT≤5的患者减量后维持应答可能性更高。

局限性

  • 减量方法和时机按方案基于52周应答状态预设,未依据其他临床因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baricitinib, an oral selective Janus kinase inhibitor, is approved to treat adults with severe alopecia areata (AA). OBJECTIVE: To report the week 152 efficacy results from the phase 3 trial BRAVE-AA2 down-titration substudy. METHODS: BRAVE-AA2 enrolled 546 adults with severe AA (Severity of Alopecia Tool [SALT] score ≥50). Baricitinib 4-mg-treated patients achieving a clinical response (SALT score ≤20) at week 52 were rerandomized 1:1 to stay on 4-mg or down-titrate to 2-mg. The last observation carried forward was used to impute missing or censored data. RESULTS: At week 52, 86/234 (36.8%) baricitinib 4-mg-treated patients were eligible for down-titration; 44 remained on 4-mg while 42 down-titrated to 2-mg. At week 152, 39/44 (88.6%) 4-mg-treated patients had maintained clinical response, compared to 24/41 (58.5%) down-titrated patients. Among down-titrated patients, loss of treatment benefit was less frequent in those with sustained response and SALT score ≤5 at week 52. LIMITATIONS: Method and timing of down-titration were prespecified in the protocol based on week 52 responder status and not on other clinical factors. CONCLUSION: More than half of down-titrated patients maintained response. Sustained treatment response and/or near-total regrowth may be associated with a greater likelihood of response maintenance after down-titration.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. King B, Ohyama M, Senna M, et al. Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2. J Am Acad Dermatol. 2024. PMID: 39447758. doi:10.1016/j.jaad.2024.09.072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。